Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease

Journal of the Formosan Medical Association

Volumn 105, Issue 5, 2006, Pages 377-383

  Liou, Jer Young ^a   Shyu, Kou Gi ^a,b   Lu, Ming Jen ^a   Chao, Hung Hsin ^a   Wang, Bao Wei ^a   Kuan, Pei Liang ^a  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Collateral circulation; Coronary artery disease; Endostatin; Vascular endothelial growth factor

Indexed keywords

ENDOSTATIN; VASCULOTROPIN;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OPEN HEART SURGERY; PATIENT CODING;

EID: 33645931644     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60133-9     Document Type: Article

References (28)

1. Coats AJS. Pericardial fluid-dispensable or indispensable fluid and an example of patentable biodiversity. Int J Cardiol 2001;77:109-11.
2. Fujita M, Kameda M, Hasegawa K, et al. Pericardial fluid as a new material for clinical heart research. Int J Cardiol 2001;77:113-8.
3. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
4. Yoon SS, Eto H, Lin CM, et al. Mouse endostatin inhibits the formation of lung and liver metastasis. Cancer Res 1999;59:6251-6.
5. Perletti G, Concari P, Giardini RJ, et al. Anti-tumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000;60:1793-6.
6. Yokoyama Y, Green JE, Sukhatme VP, et al. Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinomas in a transgenic mouse model. Cancer Res 2000; 60:4362-5.
7. Ding I, Sun JZ, Fenton B, et al. Intramural administration of endostatin plasmid inhibits vascular growth and perfusion in Mca-4 murine mammary carcinomas. Cancer Res 2001; 61:526-31.
8. Dixelius J, Larrson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000;95: 3403-11.
9. Dhar DK, Ono T, Yamanoi A, et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer 2002;95:2188-95.
10. Bono P, Teeerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003;97:2767-75.
11. Zhao J, Yan F, Ju H, et al. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 2004;204:87-95.
12. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Science 1992;359:843-5.
13. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
14. Lee SH, Wolf PL, Escudero R, et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med 2000;342:626-33.
15. Kranz-Rau C, Kochs M, Waltenberger J. Elevation of vascular endothelial growth factor-A serum levels following acute myocardial infarction. Evidence for its origin and functional significance. J Mol Cell Cardiol 2000;32:65-72.
16. Panchal VR, Rehman J, Nguyen AT, et al. Reduced pericardial levels of endostatin correlate with collateral development in patients with ischemic heart disease. J Am Coll Cardiol 2004;43:1383-7.
17. Rentrop KP, Cohen M, Blanke H, et al. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985;5:587-92.
18. Blann AD, Belgore FM, McCollum CN, et al. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci 2002;102:187-94.
19. Gerrah R, Tshori S, Gilon D. Pericardial fluid and serum VEGF in response to different types of heparin treatment. Int J Cardiol 2004;94:193-6.
20. Losordo DW, Vale PR, Symes JF, et al. Therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-4.
21. Hojo Y, Ikeda U, Zhu Y, et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol 2000;35:968-73.
22. Chilian WM, Mass HJ, Williams SE, et al. Microvascular occlusions promote collateral growth. Am J Physiol 1990; 258:H11103-11.
23. Weihrauch D, Tessmer J, Wartier, et al. Repetitive coronary artery occlusion induce release of growth factors into the myocardial interstitium. Am J Physiol 1998;275: H969-76.
24. Alber HF, Frick M, Dulak J, et al. Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease. Heart 2005;91:365-6.
25. Zachary I, Mathur A, Yla-Herttuala S, et al. Vascular protection: a novel nonangiogenic cardiovascular role for vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2000;20:1512-20.
26. Fujita M, Ikemoto M, Kishishita M, et al. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 1996;94:610-3.
27. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1997;96: 3542-8.
28. Schaper W, Ito W. Molecular mechanisms of coronary collateral vessel growth. Circ Res 1996;79:911-9.